| abstract |
The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula n n n n n n n n n n whereinn R 1 , R 2 , and R 3 , are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. nn This class of compounds has high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease. |